Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Citizen’s partnership will work with CZI’s Rare As One project, a research and funding network that includes multiple patient ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

An open-label extension study of the phase 3 ATTRibute-CM trial shows that acoramidis produced reductions of 36% and 34% in ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...